the beginning

As an Amgen company since 2011, we have been performing an essential role in the healthcare sector, promoting access to therapies for highly prevalent diseases in the population, such as the different types of cancer. And all of this is done with international standards, high quality and criteria from one of the largest biotechnology companies in the world, Amgen.

ABOUT BERGAMO
Bergamo: the beginning
With sustainable-concerned and responsible operations, we seek to reduce our impact on the environment in several areas of our business.

With sustainable-concerned and responsible operations, we seek to reduce our impact on the environment in several areas of our business.

LEARN MORE

Browse through our history

LEARN MORE

Numbers prove our commitment and dedication to patients

Dedication to patients
R$50 million

R$50 million

invested in the factory
from 2016 to 2021

23 medicines

23 medicines

in the portfolio

R$16.7 million

R$16.7 million

invested in R&D
from 2019 to 2021

25 medicines

25 medicines

marketed in
the USA

16 medicines

16 medicines

marketed in
Brazil

~100 countries

~100 countries

in which we have a commercial presence

Hopa: Hematology/Oncology Pharmacy Association

Isopp: International Society of Oncology Pharmacy Practitioners

EEP HCFUMUSP: Escola de Educação Permanente dos Hospital das Clínicas – Faculdade de Medicina da Universidade de São Paulo

ICESP: Instituto do Câncer do Estado de São Paulo

You can also access

* As an Amgen company, we have scientific innovation and continuous improvement in our DNA. Our efforts are orientated to the search for increments and improvements to our products following the goal to fulfill our mission: to serve patients.